



Albumin in Acute Stroke (ALIAS) Trial - Part 2

Project Name: A Phase III Randomized Multicenter Clinical Trial of High-Dose Human Albumin Therapy for Neuroprotection in Acute Ischemic Stroke

Project Description: To ascertain whether high-dose human albumin (ALB) therapy confers neuroprotection in acute ischemic stroke over and above best standard of care. (Specifically, to determine whether ALB therapy increases the proportion of acute ischemic stroke patients with favorable outcome compared to placebo therapy at 3 months from randomization.)

Project Period Jan. 2009 – Dec. 2013

Funding Source: National Institute of Health / National Institute of Neurological Disorders and Stroke (NIH / NINDS) [U01 NS40406](#) [U01 NS054630](#)

Principal Investigators: Myron D. Ginsberg, M.D., Study Chair
Peritz Scheinberg Professor of Neurology
University of Miami School of Medicine

Michael D. Hill, M.D., M.Sc., FRCPC, Canadian Co-PI
Associate Professor, Calgary Stroke Program

Yuko Y. Palesch, Ph.D., Biostatistics Co-PI
Division Director, Professor of Biostatistics and Epidemiology
Medical University of South Carolina

Description of DCU Responsibilities: DCU is responsible for the design, coordination, monitoring, data management and evaluation of this international multi-center trial involving 1100 participants enrolled from 100 clinical centers in the United States and Canada.